Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.
Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...
Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
A young woman was left fighting for her life after she consumed a popular energy drink while working out and then went into cardiac arrest. Jazmin Garza had a few sips of the beverage, used as a ...
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...
Jazmin Garza, 20, had a few sips of an energy drink before she began to feel unwell. Picture: Kennedy News She’s made a ‘miraculous recovery’ but has been left with huge medical bills.
Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results